DTIL · Precision BioSciences, Inc.

Precision BioSciences delivered Q1 2026 results reflecting disciplined execution amid clinical advancement. Revenues surged to $10.8 million, driven by a milestone payment under the TG Therapeutics license agreement—$7.5 million total including $5.25 million cash and $2.25 million in common stock—and legacy ARCUS agriculture collaboration revenue, a sharp rise from negligible prior-year levels. R&D expenses dipped slightly to $13.1 million from $13.6 million, with decreases in platform development offset by ramping costs for PBGENE-DMD site activation and PBGENE-HBV dosing. G&A fell more significantly to $6.8 million from $8.6 million due to operational efficiencies and lower employee costs. Other expenses ballooned to $9.4 million loss from $1.5 million income, primarily non-cash warrant liability fair value changes and reduced interest income, yielding a net loss of $18.4 million or $(0.75) per share, improved from prior year. Balance sheet remains robust with $125.8 million in cash, cash equivalents, and restricted cash, bolstered by ATM facility access, funding wholly owned PBGENE-HBV and PBGENE-DMD through 2028 data milestones. CEO Michael Amoroso highlighted progress in ELIMINATE-B (16 patients, 38 doses across cohorts) and FUNCTION-DMD (first site active, enrolling), with upcoming EASL poster on cccDNA elimination evidence and further 2026 data readouts positioning ARCUS platform for key catalysts.